Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-MV in Antiviral-Resistant CMV, BKV, or EBV Infection After Allogeneic HSCT
KCT0011031Phase 2Not yet recruiting
- Sponsor
- LucasBio
- Start
- Oct 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LB-DTK-MV in cytomegalovirus disease (CMV), BK polyomavirus infection, Epstein-Barr virus infection and 1 more, sponsored by LucasBio. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
LB-DTK-MV
03
Conditions
cytomegalovirus disease (CMV)BK polyomavirus infectionEpstein-Barr virus infectionPost-transplant viral-associated disease
Beyond the preview
Go deeper on KCT0011031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011031.